Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

The FDA accepted Breyanzi's sBLA for relapsed/refractory marginal zone lymphoma, granting priority review with a PDUFA date of December 5, 2025. Breyanzi is a CAR-T cell therapy targeting CD19, with a ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from his presentation on extranodal marginal zone ...

Please provide your email address to receive an email when new articles are posted on . In this video, Joshua Brody, MD, discusses results from the ongoing phase 2 MorningSun trial of subcutaneous ...

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...

A Prescription Drug User Fee Act target date of December 5, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...

Extranodal Marginal Zone Lymphoma: No Longer Just a Sidekick. If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply ...

The US Food and Drug Administration (FDA) has granted an accelerated approval to zanubrutinib (Brukinsa) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma ...

PLYMOUTH MEETING, PA [September 12, 2022] — The National Comprehensive Cancer Network ® (NCCN ®) has published new NCCN Guidelines for Patients ®: Marginal Zone Lymphoma. A cancer of the lymphatic ...

Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi). "Patients living with marginal zone lymphoma .